Hospital-Acquired Infection (HAI) Control Market (Disinfection, Sterilization, Treatment, Testing)

Attention: There is an updated edition available for this report.
   Single User - $4,200
   Site License (one location, 10 users) - $6,300
   Corporate License - $8,400

Published Jan 25, 2016 | 229 Pages | Pub ID: KLI5854190

Hospital-Acquired Infection (HAI) Control Market (Disinfection, Sterilization, Treatment, Testing)

Infection control in health care facilities deals largely with protecting building occupants from patients with communicable infectious diseases. Infections, which may result from activities and procedures taking place within the facility, have become a cause for great concern. Infection that is acquired during the course of health care is known as a nosocomial, or hospital acquired, infection. The infection may occur in a postoperative wound or as a complication unrelated to the disease or condition.

This Kalorama Information report, Hospital-Acquired Infections takes a solid look at

Hospital-Acquired Infection Statistics
Device Sterilization Market
Hospital Area Disinfection Market
HAI Testing Market
Treatment Market
Market Segmentation by Healthcare Location: Hospital, Nursing Home, Other
Market Segmentation by Geographic Location: US, EU, Asia, Other

There are several challenges facing the healthcare industry which contribute to the problem of healthcare-acquired infections. These are outlined below:
  • Increasing health expenditures have promoted the use of reusable medical equipment and supplies. This has inadvertently added increased risk over disposable products.
  • The aging population is increasing the need for improved HAI prevention measures. These are among the most vulnerable patients.
  • Increasing disease incidence and comorbid conditions generates a growing at-risk population for HAIs.
  • Compliance among medical staff in HAI prevention measures is still a concern, despite the growing awareness and education efforts.
  • Reducing HAIs to at or below the national average is acceptable. This may slow aggressiveness once this goal is realized.
Market analysis in this report considers primarily the epidemiological considerations and the size patient groups both in the United States and globally, where available. We have accumulated the most recent data available, understanding that virtually no organization does extensive studies on these applications on a regular basis. Many studies are highly localized and may only apply to a community, state or country (more often countries that are not a part of the major markets for nosocomial diagnostic and therapeutic products). In many instances, we have had to draw from broader epidemiologic data, that is, on data that reach outside of the hospital and primary care environment in order to construct a picture of the infection prevention, testing and treatment needs.


The area of hospital infections represents a difficult market landscape with several key trends affecting a product manufacturer’s ability to successfully operate in the market, including:
  • Development of fast testing systems
  • Growing drug resistance
  • Attention to special population issues
  • Demographics and epidemiology
  • New government guidelines and requirements for preventing infection
Special considerations must be addressed while evaluating the potential market opportunities and restraints, including:
  • Nosocomial infections are a fact of life—while the incidence of any specific nosocomial infection may decline, it will be compensated for by the rise of a new infection or an increase in the incidence of another, existing, nosocomial infection.
  • The incidence of drug-resistant nosocomial infections is on the rise and can be expected to accelerate in the near future.
  • Multi-drug- or extensive-drug-resistance will further limit the effectiveness of existing therapeutics, and require improved detection of disease and treatment plans.
  • The hospital setting is badly in need of new, rapid testing procedures to define a pathogen’s susceptibility to antibacterial treatment.
  • Other inpatient facilities, such as long-term care, are increasingly demanding products to reduce the risk of infection.
  • The hospital setting and the public health environment as a whole are in need of new antimicrobial therapeutic agents to combat infection, however the pipeline for these therapies is limited—calling for a need in prevention and detection.
  • Focus on alliances and partnerships to expand development programs.

The majority of competitive participation for hospital infection control and is in the United States and Europe. However, competition is steadily escalating in the United States and Europe, which is encouraging more participation in other areas such as Asia and Latin America. Companies included in this chapter are:
  • Advanced Sterilization Products
  • Becton Dickinson
  • Belimed AG
  • bioMerieux
  • Cantel
  • Cepheid
  • Getinge
  • Merck & Co.
  • Nordion
  • Pfizer
  • Roche
  • Sakura Seiki
  • Steris
  • TSO3
In looking at infections in the health environment, we consider the diagnostic and therapeutic technologies that are currently available and attempt to project trends for preventing, detecting and treating these infections. To some extent, we are limited by the activity of the industries associated with the activities mentioned above for these infections. For the most part, these activities are limited and the advanced technologies seen in other areas of medical application are not necessarily present in terms of microbiology.


The analysis presented in this report is based on data from a combination of company, government, industry, institutional and private sources. It includes information from extensive literature reviews and discussions with experts in the field, including microbiologists, pathologists, hospital authorities, reimbursement specialists, research scientists, business development managers and marketing managers
In this report,  {{key}} appears {{searchResults.reportMatchCounts[value]}} times